RT Journal Article
SR Electronic
T1 Expression analysis of miR-223 in plasma of patients with non-small cell lung cancer and other obstructive lung diseases
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA2795
DO 10.1183/13993003.congress-2018.PA2795
VO 52
IS suppl 62
A1 Dora Marinova
A1 Darina Kachakova
A1 Denitsa Dimitrova
A1 Aleksandar Lilov
A1 Evgeni Mekov
A1 Miroslav Mihailov
A1 Silva Giragosyan
A1 Yanina Slavova
A1 Dimitar Kostadinov
A1 Vanya Youroukova
A1 Rossen Petkov
A1 Atanaska Mitkova
A1 Radka Kaneva
A1 Vanio Mitev
YR 2018
UL http://erj.ersjournals.com/content/52/suppl_62/PA2795.abstract
AB Background: MicroRNAs are an important regulators of gene expression. They take part in various physiological and cellular processes. Different studies associate distinct expression pattern of miRNAs in lung cancer (LC), COPD and asthma.The aim in the present study was to analyse expression levels of miR-223 in plasma of patients with non-small cell LCs (NSCLC), COPD or asthma.Methods: In the current study RNA isolated from plasma of 50 patients - 20 Non SmallCell Lung Carcinomas – 10 squamous cell carcinomas and 10 adenocarcinomas, 15 COPD and 15 asthma patients and 10 healthy controls were included. Reverse transcription for synthesis of cDNA, RT-qPCR and statistical analysis were performed.Results: Decreased expression was found in 60% of NSCLCs, 64% of asthma, 69% of COPD patients. Overexpression was found in 10% of NSCLC, 7% of asthma and in 15% of COPD. The ROC curve analysis showed that the expression levels of miR-223 may be able to distinguish NSCLCs from healthy individuals - AUC=0.0690, CI 95%:0.453-0.927, p=0.095. The results of current study indicate the lack of statistically significant differences between the expression of miR-223 in plasma samples from LC, asthma and COPD and healthy controls. There were no significant correlations between miR-223 expression and TNM stage, N status, smoking history, asthma control, and COPD severity.Conclusions: MiR-223 is differently expressed in plasma from LC, COPD and asthma patients. In order to ascertain its role as biomarker for discrimination of patients analysis of enlarged sampling is necessary. Funded by Medical University, Sofia, contract Nr. 90/2016.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA2795.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).